Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pancreatic cancer
Pharma
Ipsen's Onivyde combo approved in first-line pancreatic cancer
The Onivyde combo marks the first new regimen approved specifically for first-line treatment of pancreatic cancer in more than 10 years.
Angus Liu
Feb 13, 2024 4:31pm
Exelixis ends Cabometyx study after seeing dramatic improvements
Aug 24, 2023 12:54pm
Ipsen's Onivyde turns in positive results in pancreatic cancer
Jan 20, 2023 11:21am
Ipsen's Onivyde pushes for earlier pancreatic cancer
Nov 9, 2022 12:16pm
PanCAN taps Mindy Kaling as face of 'PurpleStride' fundraiser
Mar 1, 2022 9:40am
Amgen will examine Lumakras further in pancreatic cancer
Feb 15, 2022 11:17am
